Compare Aurobindo Pharma with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs JUBILANT PHARMOVA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA JUBILANT PHARMOVA AUROBINDO PHARMA/
JUBILANT PHARMOVA
 
P/E (TTM) x 16.8 13.5 124.7% View Chart
P/BV x 3.6 2.5 144.5% View Chart
Dividend Yield % 0.3 0.6 48.9%  

Financials

 AUROBINDO PHARMA   JUBILANT PHARMOVA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
JUBILANT PHARMOVA
Mar-19
AUROBINDO PHARMA/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs830898 92.4%   
Low Rs527618 85.4%   
Sales per share (Unadj.) Rs333.9572.0 58.4%  
Earnings per share (Unadj.) Rs40.436.2 111.4%  
Cash flow per share (Unadj.) Rs51.859.5 87.0%  
Dividends per share (Unadj.) Rs2.504.50 55.6%  
Dividend yield (eoy) %0.40.6 62.0%  
Book value per share (Unadj.) Rs237.1301.9 78.5%  
Shares outstanding (eoy) m585.91159.28 367.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.3 153.4%   
Avg P/E ratio x16.820.9 80.4%  
P/CF ratio (eoy) x13.112.7 103.0%  
Price / Book Value ratio x2.92.5 114.0%  
Dividend payout %6.212.4 49.9%   
Avg Mkt Cap Rs m397,569120,694 329.4%   
No. of employees `00017.92.4 747.1%   
Total wages/salary Rs m25,84919,260 134.2%   
Avg. sales/employee Rs Th10,956.938,120.6 28.7%   
Avg. wages/employee Rs Th1,447.78,058.4 18.0%   
Avg. net profit/employee Rs Th1,324.32,414.3 54.9%   
INCOME DATA
Net Sales Rs m195,63691,108 214.7%  
Other income Rs m1,553357 434.6%   
Total revenues Rs m197,18991,466 215.6%   
Gross profit Rs m39,51917,390 227.3%  
Depreciation Rs m6,6803,709 180.1%   
Interest Rs m2,6262,198 119.5%   
Profit before tax Rs m31,76711,840 268.3%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-881-2,802 31.4%   
Tax Rs m7,2693,268 222.4%   
Profit after tax Rs m23,6455,770 409.8%  
Gross profit margin %20.219.1 105.8%  
Effective tax rate %22.927.6 82.9%   
Net profit margin %12.16.3 190.8%  
BALANCE SHEET DATA
Current assets Rs m153,64545,848 335.1%   
Current liabilities Rs m120,42920,897 576.3%   
Net working cap to sales %17.027.4 62.0%  
Current ratio x1.32.2 58.2%  
Inventory Days Days13557 238.1%  
Debtors Days Days6451 125.0%  
Net fixed assets Rs m103,90965,498 158.6%   
Share capital Rs m586159 367.8%   
"Free" reserves Rs m138,32247,930 288.6%   
Net worth Rs m138,90848,089 288.9%   
Long term debt Rs m1,80042,429 4.2%   
Total assets Rs m264,544114,685 230.7%  
Interest coverage x13.16.4 205.1%   
Debt to equity ratio x00.9 1.5%  
Sales to assets ratio x0.70.8 93.1%   
Return on assets %9.96.9 142.9%  
Return on equity %17.012.0 141.9%  
Return on capital %23.812.4 192.0%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31612,422 783.4%   
Fx outflow Rs m40,58917,227 235.6%   
Net fx Rs m56,727-4,805 -1,180.6%   
CASH FLOW
From Operations Rs m16,22011,215 144.6%  
From Investments Rs m-28,768-10,118 284.3%  
From Financial Activity Rs m19,1916,574 291.9%  
Net Cashflow Rs m6,6567,612 87.4%  

Share Holding

Indian Promoters % 54.1 45.6 118.6%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 8.0 8.7 91.4%  
FIIs % 27.7 21.2 130.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 21.1 48.3%  
Shareholders   69,601 23,815 292.3%  
Pledged promoter(s) holding % 8.6 15.9 54.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   WYETH  IPCA LABS  NATCO PHARMA  NEULAND LABS  PIRAMAL ENTERPRISES  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 441 Points Lower; Nifty Settles Below 15,000-Mark(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS